Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA just greenlit a game-changing diabetes device. Abbott's Libre Duo 10 Day is the first continuous monitor to track both blood sugar and ketone levels simultaneously, helping people with diabetes catch dangerous spikes before they spiral into diabetic ketoacidosis (DKA). The device is approved for anyone aged 2 and older and integrates with the existing Libre app.
The FDA has authorized Abbott's Libre Duo 10 Day — the world's first wearable to continuously monitor both blood glucose and ketone levels at the same time. This marks a significant leap beyond older ketone tests that only offered one-off, separate readings. Designed for a 10-day wear period, the device is approved for people aged 2 and older living with diabetes.
The real innovation here is early warning. The device sends automatic alerts when ketone levels start rising, giving patients and caregivers a heads-up before the situation escalates into diabetic ketoacidosis (DKA) — a potentially life-threatening emergency. Abbott's Chris Scoggins put it simply: "If glucose is the speedometer, ketones are like the check engine light."
Key Takeaways:
Why it matters: DKA is one of the most serious and costly complications of diabetes. A device that continuously monitors both key markers — and alerts users before a crisis hits — could meaningfully reduce emergency hospitalizations and improve day-to-day diabetes management.
